| References |
Top |
| REF 1 |
SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription. J Biol Chem. 2002 Jun 21;277(25):22330-7.
|
| REF 2 |
LGALS3BP regulates centriole biogenesis and centrosome hypertrophy in cancer cells. Nat Commun. 2013;4:1531.
|
| REF 3 |
Identification of differential proteins in nasopharyngeal carcinoma cells with p53 silence by proteome analysis. FEBS Lett. 2007 Jan 9;581(1):131-9.
|
| REF 4 |
Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO J. 1996 Apr 1;15(7):1615-24.
|
| REF 5 |
p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat Genet. 1995 Jun;10(2):188-95.
|
| REF 6 |
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med. 2004 Dec;10(12):1321-8.
|
| REF 7 |
Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science. 2003 Apr 11;300(5617):342-4.
|
| REF 8 |
Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain. Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5762-7.
|
| REF 9 |
p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell. 1998 Oct;2(4):405-15.
|
| REF 10 |
Binding and modulation of p53 by p300/CBP coactivators. Nature. 1997 Jun 19;387(6635):823-7.
|
| REF 11 |
Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53. Proc Natl Acad Sci U S A. 2007 Apr 24;104(17):7009-14.
|
| REF 12 |
Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell. 2004 Jun 11;117(6):735-48.
|
| REF 13 |
p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell. 2006 May 5;22(3):395-405.
|
| REF 14 |
MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation. J Biol Chem. 2002 Aug 23;277(34):30838-43.
|
| REF 15 |
p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol. 1999 Feb;19(2):1202-9.
|
| REF 16 |
PCAF is a coactivator for p73-mediated transactivation. Oncogene. 2003 Nov 13;22(51):8316-29.
|
| REF 17 |
Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53. Nature. 2016 Jan 28;529(7587):541-5.
|
| REF 18 |
Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8797-801.
|
| REF 19 |
Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol. 1993 Feb;13(2):775-84.
|
| REF 20 |
The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature. 2004 May 6;429(6987):86-92.
|
| REF 21 |
Autophagic degradation of the inhibitory p53 isoform 133p53 as a regulatory mechanism for p53-mediated senescence. Nat Commun. 2014 Aug 21;5:4706.
|
| REF 22 |
CHIP chaperones wild type p53 tumor suppressor protein. J Biol Chem. 2007 Sep 28;282(39):28441-54.
|
| REF 23 |
Using an in situ proximity ligation assay to systematically profile endogenous protein-protein interactions in a pathway network. J Proteome Res. 2014 Dec 5;13(12):5339-46.
|
| REF 24 |
Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Mol Cell. 2001 Sep;8(3):713-8.
|
| REF 25 |
MBP1: a novel mutant p53-specific protein partner with oncogenic properties. Oncogene. 1999 Jun 17;18(24):3608-16.
|
| REF 26 |
Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2872-7.
|
| REF 27 |
Protein interaction data set highlighted with human Ras-MAPK/PI3K signaling pathways. J Proteome Res. 2008 Sep;7(9):3879-89.
|
| REF 28 |
The UBC9 E2 SUMO conjugating enzyme binds the PR-Set7 histone methyltransferase to facilitate target gene repression. PLoS One. 2011;6(7):e22785.
|
| REF 29 |
Nedd8-modification of Cul1 is promoted by Roc1 as a Nedd8-E3 ligase and regulates its stability. Biochem Biophys Res Commun. 2003 Feb 7;301(2):392-8.
|
| REF 30 |
EDD inhibits ATM-mediated phosphorylation of p53. J Biol Chem. 2011 Apr 29;286(17):14972-82.
|
| REF 31 |
BRCA1 interaction of centrosomal protein Nlp is required for successful mitotic progression. J Biol Chem. 2009 Aug 21;284(34):22970-7.
|
| REF 32 |
TP53 Binding to BRCA1 and RAD51 in MCF7 and MDA-MB-468 Breast Cancer Cell Lines In vivo and In vitro. Avicenna J Med Biotechnol. 2015 Apr-Jun;7(2):76-9.
|
| REF 33 |
Association of p14ARF with the p120E4F transcriptional repressor enhances cell cycle inhibition. J Biol Chem. 2003 Feb 14;278(7):4981-9.
|
| REF 34 |
p53 is involved in the p120E4F-mediated growth arrest. Oncogene. 2000 Jan 13;19(2):188-99.
|
| REF 35 |
ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell. 2005 Jul 1;121(7):1071-83.
|
| REF 36 |
Multivalent binding of p53 to the STAGA complex mediates coactivator recruitment after UV damage. Mol Cell Biol. 2008 Apr;28(8):2517-27.
|
| REF 37 |
OncoPPi-informed discovery of mitogen-activated protein kinase kinase 3 as a novel binding partner of c-Myc. Oncogene. 2017 Oct 19;36(42):5852-5860.
|
| REF 38 |
A genome-scale protein interaction profile of Drosophila p53 uncovers additional nodes of the human p53 network. Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6322-7.
|
| REF 39 |
RNF38 encodes a nuclear ubiquitin protein ligase that modifies p53. Biochem Biophys Res Commun. 2013 Nov 1;440(4):473-8.
|
| REF 40 |
Bladder polypoid cystitis-derived A20 associates with tumorigenesis. Cell Biochem Biophys. 2013 Nov;67(2):669-73.
|
| REF 41 |
Structure of the Tfb1/p53 complex: Insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. Mol Cell. 2006 Jun 23;22(6):731-40.
|
| REF 42 |
Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol. 2004 May;6(5):443-50.
|
| REF 43 |
Resveratrol induces p53-independent, X-linked inhibitor of apoptosis protein (XIAP)-mediated Bax protein oligomerization on mitochondria to initiate cytochrome c release and caspase activation. J Biol Chem. 2011 Aug 19;286(33):28749-60.
|
| REF 44 |
Nuclear and cytoplasmic p53 suppress cell invasion by inhibiting respiratory complex-I activity via Bcl-2 family proteins. Oncotarget. 2014 Sep 30;5(18):8452-65.
|
| REF 45 |
Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. Genes Dev. 2010 Oct 1;24(19):2194-204.
|
| REF 46 |
A directed protein interaction network for investigating intracellular signal transduction. Sci Signal. 2011 Sep 6;4(189):rs8.
|
| REF 47 |
Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins. Biochem Biophys Res Commun. 2014 Feb 28;445(1):120-5.
|
| REF 48 |
Functional interaction between Smad3 and S100A4 (metastatin-1) for TGF-beta-mediated cancer cell invasiveness. Biochem J. 2010 Feb 24;426(3):327-35.
|
| REF 49 |
Binding to intracellular targets of the metastasis-inducing protein, S100A4 (p9Ka). Biochem Biophys Res Commun. 2001 Sep 7;286(5):1212-7.
|
| REF 50 |
Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene. 2001 Jan 11;20(2):240-51.
|
| REF 51 |
Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem. 2000 Jul 7;275(27):20436-43.
|
| REF 52 |
Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature. 2000 Nov 16;408(6810):377-81.
|
| REF 53 |
Suppression of p53 activity through the cooperative action of Ski and histone deacetylase SIRT1. J Biol Chem. 2011 Feb 25;286(8):6311-20.
|
| REF 54 |
Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 2002 May 15;21(10):2383-96.
|
| REF 55 |
Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol Cell Biol. 2008 Aug;28(15):4745-58.
|
| REF 56 |
Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J. 2004 Mar 10;23(5):1144-54.
|
| REF 57 |
Coordination of PAD4 and HDAC2 in the regulation of p53-target gene expression. Oncogene. 2010 May 27;29(21):3153-62.
|
| REF 58 |
Architecture of the human interactome defines protein communities and disease networks. Nature. 2017 May 25;545(7655):505-509.
|
| REF 59 |
Expression of a mutant p193/CUL7 molecule confers resistance to MG132- and etoposide-induced apoptosis independent of p53 or Parc binding. Biochim Biophys Acta. 2007 Mar;1773(3):358-66.
|
| REF 60 |
CUL7 is a novel antiapoptotic oncogene. Cancer Res. 2007 Oct 15;67(20):9616-22.
|
| REF 61 |
Parc: a cytoplasmic anchor for p53. Cell. 2003 Jan 10;112(1):29-40.
|
| REF 62 |
PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 2003 Feb;3(2):117-30.
|
| REF 63 |
p34 is a novel regulator of the oncogenic behavior of NEDD4-1 and PTEN. Cell Death Differ. 2014 Jan;21(1):146-60.
|
| REF 64 |
Identification of novel p53-binding proteins by biomolecular interaction analysis combined with tandem mass spectrometry. Mol Biotechnol. 2003 Mar;23(3):203-12.
|
| REF 65 |
ABRO1 suppresses tumourigenesis and regulates the DNA damage response by stabilizing p53. Nat Commun. 2014 Oct 6;5:5059.
|
| REF 66 |
Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. Cell. 2012 Aug 31;150(5):987-1001.
|
| REF 67 |
Phosphorylation and hsp90 binding mediate heat shock stabilization of p53. J Biol Chem. 2003 Jan 17;278(3):2066-71.
|
| REF 68 |
Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein. J Mol Biol. 2004 Mar 12;337(1):129-45.
|
| REF 69 |
Hsp90 chaperones wild-type p53 tumor suppressor protein. J Biol Chem. 2004 Nov 19;279(47):48836-45.
|
| REF 70 |
HSP90 Shapes the Consequences of Human Genetic Variation. Cell. 2017 Feb 23;168(5):856-866.e12.
|
| REF 71 |
p53 proteins accumulated by heat stress associate with heat shock proteins HSP72/HSC73 in human glioblastoma cell lines. Cancer Lett. 1994 Nov 25;87(1):39-46.
|
| REF 72 |
A role for Hsc70 in regulating nucleocytoplasmic transport of a temperature-sensitive p53 (p53Val-135). J Biol Chem. 2001 May 4;276(18):14649-57.
|
| REF 73 |
Hsp70 family member, mot-2/mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein. Exp Cell Res. 2002 Apr 1;274(2):246-53.
|
| REF 74 |
A human protein-protein interaction network: a resource for annotating the proteome. Cell. 2005 Sep 23;122(6):957-68.
|
| REF 75 |
The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature. 2002 Oct 24;419(6909):853-7.
|
| REF 76 |
Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J Biol Chem. 2002 Dec 13;277(50):47976-9.
|
| REF 77 |
The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53. Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10355-60.
|
| REF 78 |
Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status. Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1235-40.
|
| REF 79 |
Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function. EMBO J. 2002 Sep 2;21(17):4491-9.
|
| REF 80 |
A novel Aurora-A-mediated phosphorylation of p53 inhibits its interaction with MDM2. Biochim Biophys Acta. 2013 Feb;1834(2):508-15.
|
| REF 81 |
COP9 subunits 4 and 5 target soluble guanylyl cyclase 1 and p53 in prostate cancer cells. Mol Endocrinol. 2014 Jun;28(6):834-45.
|
| REF 82 |
Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome. EMBO J. 2003 Mar 17;22(6):1302-12.
|
| REF 83 |
Tethering function of the caspase cleavage fragment of Golgi protein p115 promotes apoptosis via a p53-dependent pathway. J Biol Chem. 2011 Mar 11;286(10):8565-76.
|
| REF 84 |
Monitoring protein-protein interactions in mammalian cells by trans-SUMOylation. Biochem J. 2011 Sep 15;438(3):495-503.
|
| REF 85 |
JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases. Oncogene. 1997 Nov 6;15(19):2277-87.
|
| REF 86 |
Control of p53 multimerization by Ubc13 is JNK-regulated. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12676-81.
|
| REF 87 |
The effect of C-terminal fragment of JNK2 on the stability of p53 and cell proliferation. Cell Res. 2004 Oct;14(5):434-8.
|
| REF 88 |
JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis. J Biol Chem. 2003 Mar 14;278(11):9195-202.
|
| REF 89 |
ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet. 1998 Dec;20(4):398-400.
|
| REF 90 |
The DNA Damage Response Regulates RAG1/2 Expression in Pre-B Cells through ATM-FOXO1 Signaling. J Immunol. 2016 Oct 1;197(7):2918-29.
|
| REF 91 |
Substrate specificities and identification of putative substrates of ATM kinase family members. J Biol Chem. 1999 Dec 31;274(53):37538-43.
|
| REF 92 |
Functional interaction of H2AX, NBS1, and p53 in ATM-dependent DNA damage responses and tumor suppression. Mol Cell Biol. 2005 Jan;25(2):661-70.
|
| REF 93 |
Regulation of NF-kappaB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO J. 2005 Mar 23;24(6):1157-69.
|
| REF 94 |
Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev. 2001 Jul 15;15(14):1833-44.
|
| REF 95 |
BRCA1-BARD1 complexes are required for p53Ser-15 phosphorylation and a G1/S arrest following ionizing radiation-induced DNA damage. J Biol Chem. 2004 Jul 23;279(30):31251-8.
|
| REF 96 |
Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol. 2002 Jan;4(1):1-10.
|
| REF 97 |
Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo. J Biol Chem. 2002 Aug 30;277(35):32020-8.
|
| REF 98 |
Radiation-induced phosphorylation of Chk1 at S345 is associated with p53-dependent cell cycle arrest pathways. Neoplasia. 2002 Mar-Apr;4(2):171-80.
|
| REF 99 |
Regulatory interactions between the checkpoint kinase Chk1 and the proteins of the DNA-dependent protein kinase complex. J Biol Chem. 2003 Aug 8;278(32):29940-7.
|
| REF 100 |
Functional interaction between BLM helicase and 53BP1 in a Chk1-mediated pathway during S-phase arrest. J Cell Biol. 2004 Sep 13;166(6):801-13.
|
| REF 101 |
UV-induced interaction between p38 MAPK and p53 serves as a molecular switch in determining cell fate. FEBS Lett. 2010 Dec 1;584(23):4711-6.
|
| REF 102 |
Essential role of p53 phosphorylation by p38 MAPK in apoptosis induction by the HIV-1 envelope. J Exp Med. 2005 Jan 17;201(2):279-89.
|
| REF 103 |
Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell. 2008 Jan 18;29(1):9-22.
|
| REF 104 |
Gene network analysis of oxidative stress-mediated drug sensitivity in resistant ovarian carcinoma cells. Pharmacogenomics J. 2010 Apr;10(2):94-104.
|
| REF 105 |
The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro. Oncogene. 1999 Apr 29;18(17):2690-702.
|
| REF 106 |
PML enhances the regulation of p53 by CK1 in response to DNA damage. Oncogene. 2008 Jun 12;27(26):3653-61.
|
| REF 107 |
Casein kinase 1 delta (CK1delta) interacts with the SNARE associated protein snapin. FEBS Lett. 2006 Nov 27;580(27):6477-84.
|
| REF 108 |
Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage. Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7951-5.
|
| REF 109 |
Downregulation of the cdc2/cyclin B protein kinase activity by binding of p53 to p34(cdc2). Biochem Biophys Res Commun. 2001 May 4;283(2):507-12.
|
| REF 110 |
The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A. J Mol Biol. 2000 Jul 14;300(3):503-18.
|
| REF 111 |
Regulation of CAK kinase activity by p53. Oncogene. 1998 Nov 26;17(21):2733-41.
|
| REF 112 |
p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner. Mol Cell Biol. 1997 Dec;17(12):7220-9.
|
| REF 113 |
The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. J Biol Chem. 2003 Aug 29;278(35):33134-41.
|
| REF 114 |
The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 2000 Feb 1;14(3):289-300.
|
| REF 115 |
MAP/ERK kinase kinase 1 (MEKK1) mediates transcriptional repression by interacting with polycystic kidney disease-1 (PKD1) promoter-bound p53 tumor suppressor protein. J Biol Chem. 2010 Dec 10;285(50):38818-31.
|
| REF 116 |
Nuclear Localization Signal and p53 Binding Site in MAP/ERK Kinase Kinase 1 (MEKK1). J Cell Biochem. 2015 Dec;116(12):2903-14.
|
| REF 117 |
The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. Mol Cell. 2001 Jun;7(6):1307-19.
|
| REF 118 |
Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function. Int J Biochem Cell Biol. 2016 Jan;70:105-17.
|
| REF 119 |
Estrogen receptor protects p53 from deactivation by human double minute-2. Cancer Res. 2000 Apr 1;60(7):1810-4.
|
| REF 120 |
Repression of hepatocyte nuclear factor 4alpha tumor suppressor p53: involvement of the ligand-binding domain and histone deacetylase activity. Mol Endocrinol. 2002 Feb;16(2):402-10.
|
| REF 121 |
An autoregulatory feedback loop between Mdm2 and SHP that fine tunes Mdm2 and SHP stability. FEBS Lett. 2012 Apr 24;586(8):1135-40.
|
| REF 122 |
Cross-regulation of protein stability by p53 and nuclear receptor SHP. PLoS One. 2012;7(6):e39789.
|
| REF 123 |
Repression of p53 activity by Smyd2-mediated methylation. Nature. 2006 Nov 30;444(7119):629-32.
|
| REF 124 |
Regulation of p53 activity through lysine methylation. Nature. 2004 Nov 18;432(7015):353-60.
|
| REF 125 |
Toward an understanding of the protein interaction network of the human liver. Mol Syst Biol. 2011 Oct 11;7:536.
|
| REF 126 |
The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase. Mol Cell Proteomics. 2008 Mar;7(3):560-72.
|
| REF 127 |
Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell. 2005 Jun 17;121(6):873-85.
|
| REF 128 |
Inhibition of human brain tumor cell growth by the anti-inflammatory drug, flurbiprofen. Oncogene. 2001 Oct 18;20(47):6864-70.
|
| REF 129 |
Cyclooxygenase-2 functionally inactivates p53 through a physical interaction with p53. Biochim Biophys Acta. 2009 Aug;1793(8):1354-65.
|
| REF 130 |
COX-2 regulates p53 activity and inhibits DNA damage-induced apoptosis. Biochem Biophys Res Commun. 2005 Mar 25;328(4):1107-12.
|
| REF 131 |
p53-targeted LSD1 functions in repression of chromatin structure and transcription in vivo. Mol Cell Biol. 2008 Sep;28(17):5139-46.
|
| REF 132 |
p53 is regulated by the lysine demethylase LSD1. Nature. 2007 Sep 6;449(7158):105-8.
|
| REF 133 |
Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature. 2002 Apr 11;416(6881):648-53.
|
| REF 134 |
Molecular recognition of p53 and MDM2 by USP7/HAUSP. Nat Struct Mol Biol. 2006 Mar;13(3):285-91.
|
| REF 135 |
Further insight into substrate recognition by USP7: structural and biochemical analysis of the HdmX and Hdm2 interactions with USP7. J Mol Biol. 2010 Oct 8;402(5):825-37.
|
| REF 136 |
C-terminal region of USP7/HAUSP is critical for deubiquitination activity and contains a second mdm2/p53 binding site. Arch Biochem Biophys. 2010 Nov 15;503(2):207-12.
|
| REF 137 |
Roles for CSN5 in control of p53/MDM2 activities. J Cell Biochem. 2008 Mar 1;103(4):1219-30.
|
| REF 138 |
COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J. 2001 Apr 2;20(7):1630-9.
|
| REF 139 |
OTUD5 regulates p53 stability by deubiquitinating p53. PLoS One. 2013 Oct 15;8(10):e77682.
|
| REF 140 |
USP10 regulates p53 localization and stability by deubiquitinating p53. Cell. 2010 Feb 5;140(3):384-96.
|
| REF 141 |
14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol. 2003 Oct;23(20):7096-107.
|
| REF 142 |
Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem. 2004 Oct 22;279(43):44475-82.
|
| REF 143 |
Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase. J Biol Chem. 2005 Jan 14;280(2):1543-51.
|
| REF 144 |
Differential effects on p53-mediated cell cycle arrest vs. apoptosis by p90. Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):18937-42.
|
| REF 145 |
Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. Mol Cell. 2007 Apr 13;26(1):75-87.
|
| REF 146 |
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011 Mar 10;471(7337):189-95.
|
| REF 147 |
Recognition of the disordered p53 transactivation domain by the transcriptional adapter zinc finger domains of CREB-binding protein. Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):E1853-62.
|
| REF 148 |
Combinatorial control of the bradykinin B2 receptor promoter by p53, CREB, KLF-4, and CBP: implications for terminal nephron differentiation. Am J Physiol Renal Physiol. 2005 May;288(5):F899-909.
|
| REF 149 |
Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation. Biochemistry. 2009 Feb 17;48(6):1244-55.
|
| REF 150 |
Graded enhancement of p53 binding to CREB-binding protein (CBP) by multisite phosphorylation. Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19290-5.
|
| REF 151 |
CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res. 1997 Sep 1;57(17):3693-6.
|
| REF 152 |
Tumor suppressor activity of AP2alpha mediated through a direct interaction with p53. J Biol Chem. 2002 Nov 22;277(47):45028-33.
|
| REF 153 |
AP2alpha alters the transcriptional activity and stability of p53. Oncogene. 2006 Apr 6;25(15):2148-59.
|
| REF 154 |
Induction of Sp1-p53 DNA-binding heterocomplexes during granulocyte/macrophage colony-stimulating factor-dependent proliferation in human erythroleukemia cell line TF-1. J Biol Chem. 1993 Apr 15;268(11):7923-8.
|
| REF 155 |
DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. Mol Cell. 2004 Dec 3;16(5):725-36.
|
| REF 156 |
The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol Cell Biol. 2003 Apr;23(8):2669-79.
|
| REF 157 |
CREB represses p53-dependent transactivation of MDM2 through the complex formation with p53 and contributes to p53-mediated apoptosis in response to glucose deprivation. Biochem Biophys Res Commun. 2011 Mar 4;406(1):79-84.
|
| REF 158 |
p53 recruitment of CREB binding protein mediated through phosphorylated CREB: a novel pathway of tumor suppressor regulation. Mol Cell Biol. 2000 Jul;20(13):4849-58.
|
| REF 159 |
Metastasis-associated protein 1 inhibits p53-induced apoptosis. Oncol Rep. 2007 Nov;18(5):1311-4.
|
| REF 160 |
Revelation of p53-independent function of MTA1 in DNA damage response via modulation of the p21 WAF1-proliferating cell nuclear antigen pathway. J Biol Chem. 2010 Mar 26;285(13):10044-52.
|
| REF 161 |
The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity. J Biol Chem. 2003 Oct 24;278(43):42560-8.
|
| REF 162 |
ATF3 represses 72-kDa type IV collagenase (MMP-2) expression by antagonizing p53-dependent trans-activation of the collagenase promoter. J Biol Chem. 2002 Mar 29;277(13):10804-12.
|
| REF 163 |
Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. Cell. 2003 May 2;113(3):301-14.
|
| REF 164 |
Differential regulation of the REG-proteasome pathway by p53/TGF- signalling and mutant p53 in cancer cells. Nat Commun. 2013;4:2667.
|
| REF 165 |
Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J Biol Chem. 2003 Apr 18;278(16):13595-8.
|
| REF 166 |
Two sequence motifs from HIF-1alpha bind to the DNA-binding site of p53. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10305-9.
|
| REF 167 |
Physical interaction between p53 and primary response gene Egr-1. Int J Oncol. 2001 Apr;18(4):863-70.
|
| REF 168 |
Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein. J Biol Chem. 2001 Mar 9;276(10):7534-40.
|
| REF 169 |
A "twist box" code of p53 inactivation: twist box: p53 interaction promotes p53 degradation. Cancer Cell. 2012 Sep 11;22(3):404-15.
|
| REF 170 |
Twist and p53 reciprocally regulate target genes via direct interaction. Oncogene. 2008 Sep 18;27(42):5543-53.
|
| REF 171 |
Dmp1 physically interacts with p53 and positively regulates p53's stability, nuclear localization, and function. Cancer Res. 2012 Apr 1;72(7):1740-50.
|
| REF 172 |
Stabilization of the p53-DNA Complex by the Nuclear Protein Dmp1. Cancer Invest. 2017 May 28;35(5):301-312.
|
| REF 173 |
Bach1 inhibits oxidative stress-induced cellular senescence by impeding p53 function on chromatin. Nat Struct Mol Biol. 2008 Dec;15(12):1246-54.
|
| REF 174 |
PATZ1 interacts with p53 and regulates expression of p53-target genes enhancing apoptosis or cell survival based on the cellular context. Cell Death Dis. 2013 Dec 12;4:e963.
|
| REF 175 |
The circadian factor Period 2 modulates p53 stability and transcriptional activity in unstressed cells. Mol Biol Cell. 2014 Oct 1;25(19):3081-93.
|
| REF 176 |
Model-driven experimental approach reveals the complex regulatory distribution of p53 by the circadian factor Period 2. Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):13516-13521.
|
| REF 177 |
BAF60a interacts with p53 to recruit the SWI/SNF complex. J Biol Chem. 2008 May 2;283(18):11924-34.
|
| REF 178 |
Transactivation by the human cytomegalovirus IE2 86-kilodalton protein requires a domain that binds to both the TATA box-binding protein and the retinoblastoma protein. J Virol. 1994 Oct;68(10):6223-31.
|
| REF 179 |
YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress. Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12165-70.
|
| REF 180 |
Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27. Am J Pathol. 2012 May;180(5):2120-33.
|
| REF 181 |
Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression. Oncogene. 2000 Dec 14;19(54):6194-202.
|
| REF 182 |
KRAB-type zinc-finger protein Apak specifically regulates p53-dependent apoptosis. Nat Cell Biol. 2009 May;11(5):580-91.
|
| REF 183 |
NUMB controls p53 tumour suppressor activity. Nature. 2008 Jan 3;451(7174):76-80.
|
| REF 184 |
Rad54B serves as a scaffold in the DNA damage response that limits checkpoint strength. Nat Commun. 2014 Nov 11;5:5426.
|
| REF 185 |
Binding induced folding in p53-MDM2 complex. J Am Chem Soc. 2007 Mar 14;129(10):2930-7.
|
| REF 186 |
Reverse MAPPIT: screening for protein-protein interaction modifiers in mammalian cells. Nat Methods. 2005 Jun;2(6):427-33.
|
| REF 187 |
Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992 Jul 2;358(6381):80-3.
|
| REF 188 |
Silencing of the SNARE protein NAPA sensitizes cancer cells to cisplatin by inducing ERK1/2 signaling, synoviolin ubiquitination and p53 accumulation. Biochem Pharmacol. 2011 Dec 1;82(11):1630-40.
|
| REF 189 |
Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. EMBO J. 2007 Jan 10;26(1):113-22.
|
| REF 190 |
Regulation of p53 level by UBE4B in breast cancer. PLoS One. 2014 Feb 26;9(2):e90154.
|
| REF 191 |
UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53. Nat Med. 2011 Mar;17(3):347-55.
|
| REF 192 |
The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function. Cell Signal. 2015 Sep;27(9):1763-71.
|
| REF 193 |
Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor. EMBO J. 2002 Jul 15;21(14):3863-72.
|
| REF 194 |
An acetyl-methyl switch drives a conformational change in p53. Structure. 2015 Feb 3;23(2):322-31.
|
| REF 195 |
Comparison of BRCT domains of BRCA1 and 53BP1: a biophysical analysis. Protein Sci. 2004 Mar;13(3):617-25.
|
| REF 196 |
Two cellular proteins that bind to wild-type but not mutant p53. Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6098-102.
|
| REF 197 |
The BioPlex Network: A Systematic Exploration of the Human Interactome. Cell. 2015 Jul 16;162(2):425-440.
|
| REF 198 |
A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell. 2010 Nov 16;18(5):411-22.
|
| REF 199 |
A versatile platform to analyze low-affinity and transient protein-protein interactions in living cells in real time. Cell Rep. 2014 Dec 11;9(5):1946-1958.
|
| REF 200 |
Structural basis of how stress-induced MDMX phosphorylation activates p53. Oncogene. 2016 Apr 14;35(15):1919-25.
|
| REF 201 |
Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. Mol Cell. 2003 Nov;12(5):1087-99.
|
| REF 202 |
HIV-1 Vpr induces ATM-dependent cellular signal with enhanced homologous recombination. Oncogene. 2007 Jan 25;26(4):477-86.
|
| REF 203 |
p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO J. 1996 Apr 15;15(8):1992-2002.
|
| REF 204 |
Identification of Daxx interacting with p73, one of the p53 family, and its regulation of p53 activity by competitive interaction with PML. Nucleic Acids Res. 2003 Sep 15;31(18):5356-67.
|
| REF 205 |
Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53. Mol Cell Biol. 2003 Jan;23(1):322-34.
|
| REF 206 |
ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase. EMBO J. 1997 Oct 1;16(19):6018-33.
|
| REF 207 |
Poly(ADP-ribose) binds to specific domains of p53 and alters its DNA binding functions. J Biol Chem. 1998 May 8;273(19):11839-43.
|
| REF 208 |
Stress-dependent nucleolin mobilization mediated by p53-nucleolin complex formation. Mol Cell Biol. 2002 Aug;22(16):6014-22.
|
| REF 209 |
HAUSP-nucleolin interaction is regulated by p53-Mdm2 complex in response to DNA damage response. Sci Rep. 2015 Aug 4;5:12793.
|
| REF 210 |
Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol. 2002 Jul;4(7):529-33.
|
| REF 211 |
Characterisation of the interface between nucleophosmin (NPM) and p53: potential role in p53 stabilisation. FEBS Lett. 2006 Jan 9;580(1):345-50.
|
| REF 212 |
Proteomic dissection of the von Hippel-Lindau (VHL) interactome. J Proteome Res. 2011 Nov 4;10(11):5175-82.
|
| REF 213 |
Factor inhibiting HIF-1 (FIH-1) modulates protein interactions of apoptosis-stimulating p53 binding protein 2 (ASPP2). J Cell Sci. 2013 Jun 15;126(Pt 12):2629-40.
|
| REF 214 |
A novel mutant p53 binding partner BAG5 stabilizes mutant p53 and promotes mutant p53 GOFs in tumorigenesis. Cell Discov. 2016 Nov 1;2:16039.
|
| REF 215 |
The function of PML in p53-dependent apoptosis. Nat Cell Biol. 2000 Oct;2(10):730-6.
|
| REF 216 |
Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and p53. Mol Cell Biol. 1994 Oct;14(10):7013-24.
|
| REF 217 |
DNA damage tolerance pathway involving DNA polymerase and the tumor suppressor p53 regulates DNA replication fork progression. Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):E4311-9.
|
| REF 218 |
A direct interaction between the survival motor neuron protein and p53 and its relationship to spinal muscular atrophy. J Biol Chem. 2002 Jan 25;277(4):2852-9.
|
| REF 219 |
Acetylation-regulated interaction between p53 and SET reveals a widespread regulatory mode. Nature. 2016 Oct 6;538(7623):118-122.
|
| REF 220 |
SOCS1 links cytokine signaling to p53 and senescence. Mol Cell. 2009 Dec 11;36(5):754-67.
|
| REF 221 |
AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation. Oncogene. 2011 Mar 10;30(10):1194-204.
|
| REF 222 |
MDM2 Inhibits Axin-Induced p53 Activation Independently of its E3 Ligase Activity. PLoS One. 2013 Jun 27;8(6):e67529.
|
| REF 223 |
DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway. Nat Cell Biol. 2016 Nov;18(11):1233-1243.
|
| REF 224 |
Activation of p53 or loss of the Cockayne syndrome group B repair protein causes metaphase fragility of human U1, U2, and 5S genes. Mol Cell. 2000 May;5(5):801-10.
|
| REF 225 |
SUMOylation of hnRNP-K is required for p53-mediated cell-cycle arrest in response to DNA damage. EMBO J. 2012 Nov 28;31(23):4441-52.
|
| REF 226 |
iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet. 2003 Feb;33(2):162-7.
|
| REF 227 |
p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res. 2003 May 15;63(10):2373-8.
|
| REF 228 |
Nuclear localization signal of ING4 plays a key role in its binding to p53. Biochem Biophys Res Commun. 2005 Jun 17;331(4):1032-8.
|
| REF 229 |
Necdin controls proliferation and apoptosis of embryonic neural stem cells in an oxygen tension-dependent manner. J Neurosci. 2013 Jun 19;33(25):10362-73.
|
| REF 230 |
Physical and functional interactions of neuronal growth suppressor necdin with p53. J Biol Chem. 1999 Jun 4;274(23):16242-8.
|
| REF 231 |
The proto-oncogene PBF binds p53 and is associated with prognostic features in colorectal cancer. Mol Carcinog. 2016 Jan;55(1):15-26.
|
| REF 232 |
The PTTG1-binding factor (PBF/PTTG1IP) regulates p53 activity in thyroid cells. Endocrinology. 2014 Apr;155(4):1222-34.
|
| REF 233 |
SET1 and p300 act synergistically, through coupled histone modifications, in transcriptional activation by p53. Cell. 2013 Jul 18;154(2):297-310.
|
| REF 234 |
The interaction of p53 with replication protein A mediates suppression of homologous recombination. Oncogene. 2004 Dec 2;23(56):9025-33.
|
| REF 235 |
Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci U S A. 1995 May 23;92(11):5154-8.
|
| REF 236 |
Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem. 2001 Feb 2;276(5):3361-70.
|
